WORCESTER, MA — (BUSINESS WIRE) Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC) announced today that it has completed key animal studies…
Study suggests hESCs could serve as a safe source of cells to treat diseases of the eye WORCESTER, Mass.– (BUSINESS…
Third Stargardt’s Patient in EU Trial Treated with RPE Cells Derived from Human Embryonic Stem Cells at Moorfields Eye Hospital…
Ideal candidate for early clinical trials involving iPS cells MARLBOROUGH, MA – January 11, 2011. Advanced Cell Technology, Inc. (OTCBB:ACTC)…
MARLBOROUGH, Mass. — Jan. 25, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative…
UCLA’s Investigator IND Application for Embryonic Stem Cell-Based Clinical Trial to Evaluate Safety and Tolerability in Patients with Severe Myopia,…
Phase 1/2 Clinical Trials of RPE Cells for the Treatment of Dry Age-Related Macular Degeneration and Stargardt’s Macular Degeneration Show Positive Long…
Company Continues to Leverage IP Portfolio LOS ANGELES—(BUSINESS WIRE)—Advanced Cell Technology, Inc.(OTCBB: ACTC – News) announced today that it has entered into an…
Data and Safety Monitoring Board (DSMB) Grants Approval to Proceed with Treatment of Second Patient Cohort MARLBOROUGH, Mass. — July…
MARLBOROUGH, Mass. – July 2, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative…